Back to results
US 2014/0228398 A1Published application
COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
AssigneeNovartis AG
InventorsTherese Di Paolo, Baltazar Gomez-Mancilla, Cristina Lopez-Lopez, Donal Johns
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.
Claims8
A combination, which comprises:
- (A) at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator, selected from a nicotinic acetylcholine receptor alpha 7 agonist and a nicotinic acetylcholine receptor alpha 7 positive allosteric modulator, as the first active ingredient;
- and
- (B) at least one low molecular weight metabotropic glutamate receptor 5 antagonist as the second active ingredient;
- in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt;
- for the use as a medicament.
2 more elements
A combination, which comprises:
- (A) at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator, selected from a nicotinic acetylcholine receptor alpha 7 agonist and a nicotinic acetylcholine receptor alpha 7 positive allosteric modulator, as the first active ingredient;
- and
- (B) at least one low molecular weight metabotropic glutamate receptor 5 antagonist as the second active ingredient;
- in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt;
- for use in the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
2 more elements
A combination, which comprises:
- (A) at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator, selected from a nicotinic acetylcholine receptor alpha 7 agonist and a nicotinic acetylcholine receptor alpha 7 positive allosteric modulator, as the first active ingredient;
- and
- (B) at least one low molecular weight metabotropic glutamate receptor 5 antagonist as the second active ingredient;
- in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt;
- and wherein the combination is not
- a combination comprising nicotine and methyl-6-(phenylethynyl)pyridine;
- or
- a combination comprising nicotine and 2-[(1S,2S)-2-carboxycyclopropyl]-3-(9H-xanthen-9-yl)-D-alanine.
5 more elements
Dependencies are inferred from the claim text.